Founded in 2020 through the strategic combination of Health in Code, Imegen, Genycell Biotech, and later Genologica, HiC has become a leading player in genetic diagnostics and precision medicine. Headquartered in Valencia, Spain, the company has built an integrated model combining Next-Generation sequencing1 (NGS)-based diagnostic services, genetic testing kits/panels, and proprietary bioinformatics and clinical interpretation. Thereby, HiC’s solution accelerates and improves diagnostics for patients, providing rapid, high-confidence results that support more effective clinical decisions.
The company partners primarily with public hospitals, providing end-to-end genetic testing services from sample preparation, proprietary NGS panels and kits, or bioinformatics software,to the delivery of clinical reports. Furthermore, HiC has developed a differentiated commercial model through its Rental Reagent Program, under which it supports hospitals with sequencing workflows through long-term partnerships, bundling equipment access with consumables, its proprietary DataGenomics platforms, and related services.
Buyout
Current
Europe
Minority
Life Science Tools, MedTech & Diagnostics
2026
Status
Creation Date
Number of Employees
Investment Date
Fund Name